Search: onr:"swepub:oai:lup.lub.lu.se:da74600a-c228-464d-a33d-154ee3aa8230" >
Alzheimers sjukdom ...
Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden
-
- Bogdanovic, Nenad (author)
- Karolinska Institute,Karolinska University Hospital
-
- Hansson, Oskar (author)
- Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Zetterberg, Henrik (author)
- University of Gothenburg,Sahlgrenska University Hospital
-
show more...
-
- Basun, Hans (author)
- BioArctic AB
-
- Ingelsson, Martin (author)
- Uppsala University
-
- Lannfelt, Lars (author)
- Uppsala University,BioArctic AB
-
- Blennow, Kaj (author)
- University of Gothenburg,Sahlgrenska University Hospital
-
show less...
-
(creator_code:org_t)
- 2020
- 2020
- Swedish.
-
In: Läkartidningen. - 0023-7205. ; 117
- Related links:
-
https://lakartidning... (free)
-
show more...
-
https://lup.lub.lu.s...
-
show less...
Abstract
Subject headings
Close
- Alzheimer's disease is the most common cause of dementia. As many as 250,000 people in Sweden will have a dementia disease in 2050. The »amyloid cascade hypothesis« is a common model which explains how β-amyloid affects the function of the nerve cells. Alzheimer's disease has a long-lasting course and can present in typical and atypical forms. CSF analyses for »core AD CSF biomarkers« and synaptic proteins have been available for clinical diagnostics. PET scanning can detect either β-amyloid or tau aggregates in the brain of living humans. Current Alzheimer's disease therapy is based on two classes of cognition-enhancing drugs: acetylcholinesterase inhibitor and NMDA-receptor antagonist, which delays cognitive decline in most patients. The latest clinical development of potential therapy for Alzheimer's is active or passive immunotherapy against brain β-amyloid and tau, where several studies have shown varying but promising treatment effects. Non-pharmacological interventions in patients with AD aim to delay the loss of mental abilities, helping people to be independent in everyday life for as long as possible, and to increase their well-being and quality of life.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database